Christian Hall, MD
Otolaryngology · Baton Rouge, LANPI 1134282957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,280, 3.0 times the $434 reported in 2019.
Across 232 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$1K
- GSK$632
- Spirair, Inc.$575
- Regeneron Healthcare Solutions, Inc.$533
- Sanofi$475
- Medtronic$347
- plus $2K from 22 others
What the payments were for
- Consulting fees$5009%
- Food & beverage$4,86290%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 73 | $1,240 |
| GSK | 33 | $632 |
| Spirair, Inc. | 2 | $575 |
| Regeneron Healthcare Solutions, Inc. | 25 | $533 |
| Sanofi | 21 | $475 |
| Medtronic(2 entities) | 5 | $347 |
| Aerin Medical Inc. | 11 | $263 |
| Alk-abello, Inc | 12 | $216 |
| Acclarent, Inc | 7 | $186 |
| Inspire Medical Systems, Inc. | 4 | $149 |
| Novartis | 7 | $141 |
| Stryker | 4 | $137 |
| Biohaven Pharmaceuticals, Inc. | 5 | $79 |
| AbbVie | 3 | $55 |
| Kaleo, Inc. | 2 | $42 |
| USWM, LLC | 2 | $42 |
| Amgen | 1 | $34 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Merck | 2 | $31 |
| AstraZeneca | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Integra Lifesciences Corporation | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| ICU Medical Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Pfizer | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Almirall LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,396 in reported general payments places this provider in the 85th percentile of 218 otolaryngology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 21 | $99,175 |
| NucalaMepolizumab | 12 | $44,266 |
| Ipratropium Bromide | 117 | $3,623 |
| Azelastine Hcl | 114 | $3,235 |
| Budesonide | 18 | $2,145 |
| Epinephrine | 11 | $2,105 |
| Fluticasone Propionate | 101 | $1,252 |
| Fluocinolone Acetonide Oil | 18 | $961 |
| CefuroximeCefuroxime Axetil | 89 | $863 |
| Doxycycline Monohydrate | 45 | $655 |
| Mupirocin | 58 | $479 |
| Levocetirizine Dihydrochloride | 57 | $452 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 13 | $363 |
| Methylprednisolone | 48 | $326 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 52 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala | $632 | $44,26612 claims |
| Hikma Pharmaceuticals USAEpinephrine | $34 | $2,10511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 otolaryngology providers in Louisiana.
Other otolaryngology in Baton Rouge
- Henry BarhamBaton Rouge$32K
- James LinBaton Rouge$19K
- Andrew McWhorterBaton Rouge$12K
- Collin SuttonBaton Rouge$10K
- Geoffrey PetersBaton Rouge$7K
- Rula MuallaBaton Rouge$6K
- Stephen HernandezBaton Rouge$6K
- Benjamin WaltonBaton Rouge$5K
- Elliot HardyBaton Rouge$3K
- John WoodBaton Rouge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.